All Relations between Schizophrenia and Amisulpride

Publication Sentence Publish Date Extraction Date Species
Stephan Heres, Joachim Cordes, Sandra Feyerabend, Christian Schmidt-Kraepelin, Richard Musil, Michael Riedel, Ilja Spellmann, Berthold Langguth, Michael Landgrebe, Elmar Fran, Camelia Petcu C, Eric Hahn, Tam M T Ta, Valentin Matei, Liana Dehelean, Ion Papava, F Markus Leweke, Till van der List, Simona C Tamasan, Fabian U Lang, Dieter Naber, Stephan Ruhrmann, Claus Wolff-Menzler, Georg Juckel, Maria Ladea, Cristinel Stefanescu, Marion Lautenschlager, Michael Bauer, Daisy Zamora, Mark Horowitz, John M Davis, Stefan Leuch. Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia. Schizophrenia bulletin. 2022-07-20. PMID:35857811. changing the antipsychotic in early nonimprovers to amisulpride or olanzapine: randomized, double-blind trial in patients with schizophrenia. 2022-07-20 2023-08-14 Not clear
Sukhpreet Poonia, Mazen Sharaf, Ric M Procyshyn, Randal White, Reza Rafizade. Amisulpride Augmentation of Clozapine in Clozapine-Resistant Schizophrenia: A Case Series. The Canadian journal of hospital pharmacy. vol 75. issue 3. 2022-07-18. PMID:35847467. amisulpride augmentation of clozapine in clozapine-resistant schizophrenia: a case series. 2022-07-18 2023-08-14 Not clear
Lukasz Biernat, Vincent T Grattan, Mark S Hixon, Zachary Prensky, Andrew R Vain. A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D Psychopharmacology. 2022-07-16. PMID:35841422. a randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of lb-102, a selective dopamine d lb-102 is an n-methylated analogue of amisulpride under development to treat schizophrenia. 2022-07-16 2023-08-14 human
Kankan Qu, Qin Zhou, Lin Tian, Yuan Shen, Zhenhe Zho. Amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data. International clinical psychopharmacology. 2022-07-02. PMID:35779068. amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data. 2022-07-02 2023-08-14 Not clear
Kankan Qu, Qin Zhou, Lin Tian, Yuan Shen, Zhenhe Zho. Amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data. International clinical psychopharmacology. 2022-07-02. PMID:35779068. the aim of the study was to evaluate the reference range of amisulpride for chinese patients with schizophrenia and to assess its possible influencing factors based on therapeutic drug monitoring information. 2022-07-02 2023-08-14 Not clear
Kankan Qu, Qin Zhou, Lin Tian, Yuan Shen, Zhenhe Zho. Amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data. International clinical psychopharmacology. 2022-07-02. PMID:35779068. a total of 425 patients with schizophrenia were assessed, including positive and negative syndrome scales, treatment emergent symptom scale, blood routine examination, hepatorenal function, lipids, hormones, as well as myocardial enzymes at baseline, and following treatment with amisulpride for 8 weeks. 2022-07-02 2023-08-14 Not clear
Kankan Qu, Qin Zhou, Lin Tian, Yuan Shen, Zhenhe Zho. Amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data. International clinical psychopharmacology. 2022-07-02. PMID:35779068. the therapeutic reference range of amisulpride can be defined as 230.3-527.1 ng/ml for chinese patients with schizophrenia. 2022-07-02 2023-08-14 Not clear
Kankan Qu, Qin Zhou, Lin Tian, Yuan Shen, Zhenhe Zho. Amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data. International clinical psychopharmacology. 2022-07-02. PMID:35779068. these findings could provide individualized medication and reduce the adverse effects of amisulpride for chinese patients with schizophrenia. 2022-07-02 2023-08-14 Not clear
Li-Yu Hu, Chen-Jee Hong, Shih-Jen Tsai, Cheng-Che She. Rechallenge with Amisulpride in a Patient with Schizophrenia following a Manic Episode during Previous Therapy. Case reports in psychiatry. vol 2022. 2022-05-26. PMID:35615528. rechallenge with amisulpride in a patient with schizophrenia following a manic episode during previous therapy. 2022-05-26 2023-08-13 Not clear
Jinchi Zheng, Zeya Lin, Chih-Yuan Ko, Jian-Hua Xu, Yichuan Lin, Jinyi Wan. Analysis of Gut Microbiota in Patients with Exacerbated Symptoms of Schizophrenia following Therapy with Amisulpride: A Pilot Study. Behavioural neurology. vol 2022. 2022-03-15. PMID:35287288. analysis of gut microbiota in patients with exacerbated symptoms of schizophrenia following therapy with amisulpride: a pilot study. 2022-03-15 2023-08-13 Not clear
Jinchi Zheng, Zeya Lin, Chih-Yuan Ko, Jian-Hua Xu, Yichuan Lin, Jinyi Wan. Analysis of Gut Microbiota in Patients with Exacerbated Symptoms of Schizophrenia following Therapy with Amisulpride: A Pilot Study. Behavioural neurology. vol 2022. 2022-03-15. PMID:35287288. this study was aimed at analyzing cytokines and fecal microbiota in patients with exacerbated symptoms of schizophrenia treated with amisulpride during four weeks of their hospital stay. 2022-03-15 2023-08-13 Not clear
Jinchi Zheng, Zeya Lin, Chih-Yuan Ko, Jian-Hua Xu, Yichuan Lin, Jinyi Wan. Analysis of Gut Microbiota in Patients with Exacerbated Symptoms of Schizophrenia following Therapy with Amisulpride: A Pilot Study. Behavioural neurology. vol 2022. 2022-03-15. PMID:35287288. we found that patients undergoing treatment of schizophrenia with amisulpride had distinct changes in gut microbial composition at the genus level, increased levels of short-chain fatty acid-producing bacteria ( 2022-03-15 2023-08-13 Not clear
Christian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Pablo-Emilio Verde, Christoph U Correll, Michael Kluge, Christian Makiol, Andrea Neff, Christina Lange, Susanne Englisch, Mathias Zink, Berthold Langguth, Timm B Poeppl, Dirk Reske, Euphrosyne Gouzoulis-Mayfrank, Gerhard Gründer, Alkomiet Hasan, Anke Brockhaus-Dumke, Markus Jäger, Jessica Baumgärtner, Stefan Leucht, Joachim Corde. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. The lancet. Psychiatry. 2022-03-11. PMID:35276079. amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in germany (combine): a double-blind randomised controlled trial. 2022-03-11 2023-08-13 Not clear
Bozhi Yuan, Mei Yua. Changes of Mental State and Serum Prolactin Levels in Patients with Schizophrenia and Depression after Receiving the Combination Therapy of Amisulpride and Chloroprothixol Tablets. Computational and mathematical methods in medicine. vol 2022. 2022-03-04. PMID:35242209. changes of mental state and serum prolactin levels in patients with schizophrenia and depression after receiving the combination therapy of amisulpride and chloroprothixol tablets. 2022-03-04 2023-08-13 Not clear
Bozhi Yuan, Mei Yua. Changes of Mental State and Serum Prolactin Levels in Patients with Schizophrenia and Depression after Receiving the Combination Therapy of Amisulpride and Chloroprothixol Tablets. Computational and mathematical methods in medicine. vol 2022. 2022-03-04. PMID:35242209. to investigate the changes in mental state and serum prolactin levels in patients with schizophrenia and depression after receiving the combination therapy of amisulpride and chloroprothixol tablets. 2022-03-04 2023-08-13 Not clear
Jia-Wu Ji, Li-Ying Liu, Kai-Rong Hao, Yin-Liang Yu, Sai-Zheng Weng, Jian-Fan Wu, Reng-Chun Huan. Prediction of Self-Report Cognitive Function for the Symptomatic Remission in Schizophrenia Treated with Amisulpride: a Multicenter, 8-Week Case-Control Study. The Psychiatric quarterly. vol 92. issue 3. 2021-11-25. PMID:33389476. prediction of self-report cognitive function for the symptomatic remission in schizophrenia treated with amisulpride: a multicenter, 8-week case-control study. 2021-11-25 2023-08-13 Not clear
Jia-Wu Ji, Li-Ying Liu, Kai-Rong Hao, Yin-Liang Yu, Sai-Zheng Weng, Jian-Fan Wu, Reng-Chun Huan. Prediction of Self-Report Cognitive Function for the Symptomatic Remission in Schizophrenia Treated with Amisulpride: a Multicenter, 8-Week Case-Control Study. The Psychiatric quarterly. vol 92. issue 3. 2021-11-25. PMID:33389476. patients with dsm-iv schizophrenia diagnoses who received amisulpride treatment, were recruited. 2021-11-25 2023-08-13 Not clear
Jia-Wu Ji, Li-Ying Liu, Kai-Rong Hao, Yin-Liang Yu, Sai-Zheng Weng, Jian-Fan Wu, Reng-Chun Huan. Prediction of Self-Report Cognitive Function for the Symptomatic Remission in Schizophrenia Treated with Amisulpride: a Multicenter, 8-Week Case-Control Study. The Psychiatric quarterly. vol 92. issue 3. 2021-11-25. PMID:33389476. there were no significant differences in gender composition, age, bmi, education level, age-onset, a daily dose of amisulpride and the percentage of pdq20 improvement between remission and nonremission in criteria a or criteria b. receiver operating characteristic(roc) curves were found for pdq20(day0) to define the precise scores to predict remission of schizophrenia (criteria a:auc = 0.614, s.e. 2021-11-25 2023-08-13 Not clear
Seon-Cheol Park, Bong Ju Lee, Jae Hong Park, Hiroaki Kawasaki, Ajit Avasthi, Sandeep Grover, Andi J Tanra, Shih-Ku Lin, Afzal Javed, Chay Hoon Tan, Norman Sartorius, Naotaka Shinfuku, Yong Chon Par. QT interval prolongation noted in one percent of 2553 Asian patients with schizophrenia: Findings from the REAP-AP survey. The Kaohsiung journal of medical sciences. vol 36. issue 12. 2021-10-07. PMID:32772489. schizophrenia patients were characterized by lower proportions of disorganized speech and negative symptoms; higher use of amisulpride and clozapine; and higher proportions of rigidity, hypercholesterolemia, and sedation than those without qtc prolongation. 2021-10-07 2023-08-13 Not clear
Seon-Cheol Park, Bong Ju Lee, Jae Hong Park, Hiroaki Kawasaki, Ajit Avasthi, Sandeep Grover, Andi J Tanra, Shih-Ku Lin, Afzal Javed, Chay Hoon Tan, Norman Sartorius, Naotaka Shinfuku, Yong Chon Par. QT interval prolongation noted in one percent of 2553 Asian patients with schizophrenia: Findings from the REAP-AP survey. The Kaohsiung journal of medical sciences. vol 36. issue 12. 2021-10-07. PMID:32772489. finally, a binary logistic mode showed that amisulpride, clozapine, rigidity, and hypercholesterolemia might be the distinctive clinical correlates of qtc prolongation in asian patients with schizophrenia. 2021-10-07 2023-08-13 Not clear